RESEARCH PAPER

β1-adrenergic receptor activation enhances memory in Alzheimer’s disease model

Laurence Coutellier1, Pooneh Memar Ardestani1,2, Mehrdad Shamloo1,2

1Behavioral and Functional Neuroscience Laboratory, Stanford University School of Medicine, Stanford, California
2Department of Neurosurgery, Stanford University School of Medicine, Stanford, California

Abstract

Objective: Deficits in social recognition and learning of social cues are major symptoms of neurodegenerative disorders such as Alzheimer’s disease (AD). Here, we studied the role of β1-noradrenergic signaling in cognitive function to determine whether it could be used as a potential therapeutic target for AD.

Methods: Using pharmacological, biochemical, and behavioral tools, we assessed social recognition and the β1-adrenergic receptor (ADR) and its downstream protein kinase A (PKA)/phospho-cAMP response element-binding protein (pCREB) signaling cascade in the medial amygdala (MeA) in Thy1-hAPPLOND/Swe+ (APP) mouse model of AD. Results: Our results demonstrated that APP mice display a significant social recognition deficit which is dependent on the β1-adrenergic system. Moreover, betaxolol, a selective β1-ADR antagonist, impaired social but not object/odor learning in C57Bl/6 mice. Our results identify activation of the PKA/pCREB downstream of β1-ADR in MeA as responsible signaling cascade for learning of social cues in MeA. Finally, we found that xamoterol, a selective β1-ADR partial agonist, rescued the social recognition deficit of APP mice by increasing nuclear pCREB. Interpretation: Our data indicate that activation of β1-ADR in MeA is essential for learning of social cues, and that an impairment of this cascade in AD may contribute to pathogenesis and cognitive deficits. Therefore, selective activation of β1-ADR may be used as a therapeutic approach to rescue memory deficits in AD. Further safety and translational studies will be needed to ensure the safety of this approach.

Introduction

The inability to recognize faces (social recognition) is a defined endophenotype of several neurological disorders including Alzheimer’s disease (AD).1,2 Yet, the underlying causes of this symptom remain elusive. Several studies have highlighted the role of oxytocin and vasopressin in social recognition3,4 and show that low levels of oxytocin could be responsible for deficits in face recognition in autistic patients.5 However, in AD patients, postmortem studies failed to show differences in central vasopressin and oxytocin concentration6 except in the hippocampus where levels were higher than in normal patients.7 This indicates that variations in oxytocin levels do not underlie the deficit in social recognition in AD and points to our incomplete understanding of the neural circuitries responsible for social recognition.

A well-defined pathological hallmark of AD is the degeneration of the neurons in the locus coeruleus, the main source of noradrenaline (NA) in the brain.8,9 This degeneration is associated with a subsequent reduction in NA and reduced activation of the adrenergic receptors. Adrenergic receptors mediate distinctive actions of NA via various intracellular signaling pathways and play important roles in learning and memory processes.10 Recently the contribution of the β-adrenergic system specifically the β1-adrenergic receptor (β1-ADR) in cognitive functions has received interest. For instance, NA action on β-ADR modulates inhibitory synaptic function.11 Other studies have shown that the β1-selective antagonist betaxolol produces spatial navigation retrieval deficit in wild-type (WT) mice and rats, while the retrieval deficit observed in mice with NA deficiency can be rescued by the β1-partial agonist xamoterol.12 Similarly, the cognitive deficits of the Ts65Dn mouse model
of Down syndrome, with a similar age-dependent loss of NA-containing neurons,\textsuperscript{13} can be rescued with xamoterol.\textsuperscript{14,15} These results indicate that the NAergic neurotransmission mediated by the $\beta_1$-ADR may play a predominant role in the cognitive deficits observed in neurological disorders characterized by NAergic degeneration.

In this study, we aimed to characterize the role of $\beta_1$-ADR in social recognition and memory in AD and as a potential therapeutic target. Polymorphisms in the gene coding for the $\beta_1$-ADR produce AD susceptibility by changing the cell responsiveness to adrenergic stimulation\textsuperscript{16} pointing to a predominant role of this noradrenergic receptor in AD. Furthermore, the importance of NAergic neurotransmission for social memory has been demonstrated in mouse model of locus coeruleus lesion and in transgenic mice lacking the dopamine beta-hydroxylase.\textsuperscript{17,18} We thus investigated the social recognition/memory in the Thy1-APP\textsuperscript{Lond/Swe} (APP) mouse model of AD using pharmacological and molecular tools and showed the social recognition deficit observed in APP mice is associated with abnormalities in $\beta_1$-ADR signaling in the medial amygdala (MeA). Pharmacological activation of the $\beta_1$-ADR and restoring the protein kinase A (PKA)/phospho-cAMP response element-binding protein (pCREB) levels in APP mice rescue the social memory deficit detected in this model of AD. Our results demonstrate for the first time that the $\beta_1$-ADR and CREB phosphorylation in the MeA is an essential signaling cascade for social learning under normal brain function.

\section*{Materials and Methods}

\subsection*{Animals}

Eight to 10-weeks-old adult C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME, \#000664), 8–10-week-old $\beta_2$-ADR (knockout) KO mice (kindly provided by Dr. Rona G., Giffard, Department of Anesthesia, Stanford University School of Medicine), 8–10-week-old $\beta_1$-ADR KO mice (kindly provided by Dr. Daniel Bernstein, Division of Pediatric Cardiology, Stanford University School of Medicine) and their age-matched controls (FVB/NJ mice from Jackson Laboratory, \#001800), and Thy1-hAPP\textsuperscript{Lond/Swe+} and their age-matched WT littermate mice, model of AD\textsuperscript{19} were used. This particular mouse line was chosen because it was shown to have an accelerated pathology with a rapid appearance of mature $\beta$-amyloid plaques in the frontal cortex as early as 3 months of age and in the hippocampus, thalamus, and olfactory region in 5–7 months of age.\textsuperscript{19} In addition, our previous research demonstrated severe cognitive impairments (including social memory deficits) as early as 6 months of age.\textsuperscript{20} Experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Stanford University and were performed based on the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

\subsection*{Behavioral testing}

Social recognition was tested in two different tasks: the three-chamber social test developed by Nadler \textit{et al.}\textsuperscript{21} and the in-home cage social discrimination task developed by Macbeth \textit{et al.}\textsuperscript{22} (Data S1). To differentiate between social recognition and recognition of nonsocial odors/objects, nonsocial odor discrimination tests (olfactory habituation/dishabituation and olfactory recognition test), and an object recognition test were used (Data S1).

\subsection*{Drug treatment}

The $\beta_1$-ADR partial agonist, xamoterol, the $\beta_1$-ADR antagonist, betaxolol and the PKA inhibitor, PKI 14-22 amide myristoylated (Tocris bioscience, Minneapolis, MN) were used. Xamoterol was injected subcutaneously (3 mg/kg). Betaxolol was injected subcutaneously (1 mg/kg) or in the MeA (30 nmole/side). PKI 14-22 amide was dissolved in 30% acetonitrile and injected in the MeA (2.75 nmole/side) (Data S1).

\subsection*{Molecular analyses}

Immunohistochemistry was used to assess c-Fos. The quantitative analysis of stained cells was done in different brain regions according to the Mouse Brain Atlas.\textsuperscript{23} Cell counting was achieved using the unbiased-stereologic method. The total number of positive cells was quantified with the optical fractionator method\textsuperscript{24} using Stereoinvestigator software (MBF Bioscience, Williston, VT). The counting criteria were determined so as to obtain a mean coefficient of error\textsuperscript{25} $\leq$0.10. Analysis of pCREB was performed by western blot (Data S1).

\subsection*{Statistics}

Data were analyzed using the software Prism 5.01 (GraphPad Software Inc., La Jolla, CA). For behavioral and pharmacological testing, a minimum of five animals per group were used. For immunohistochemistry and western blot four to six animals per group were used.

\subsection*{Results}

\textbf{Social recognition is impaired in a mouse model of AD}

In rodents, social recognition can be measured by an increased amount of time investigating a never-met...
conspecific as compared to a previously met one. We first investigated the ability of the APP mice to recognize a previously met conspecific. While they showed a preference for an unfamiliar intruder over an empty cup (Fig. 1A), they failed to demonstrate a preference for a new intruder over a familiar one, indicative of social recognition deficit (Fig. 1B). This deficit was not linked to a deficit in olfactory abilities or in discriminating between

**Figure 1.** APP mouse model of Alzheimer’s disease are characterized by impaired social recognition. On the left, schematic representations of the experiments are shown. (A) Both wild-type (WT; n = 11) and APP (n = 9) mice explored a cup containing an unfamiliar C57Bl/6 intruder mouse over an empty cup, showing normal sociability (two-way ANOVA: interaction P = 0.1091, F<sub>1,36</sub> = 2.699; object P < 0.0001, F<sub>1,36</sub> = 203.9; genotype P < 0.0001, F<sub>1,36</sub> = 19.43. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT P < 0.001; APP P < 0.001); (B) however, while WT showed a preference for a novel C56Bl/6 intruder over a familiar one, APP mice did not display this preference, indicative of social recognition deficits (two-way ANOVA: interaction P = 0.0112, F<sub>1,36</sub> = 7.141; object P = 0.2149, F<sub>1,36</sub> = 1.594; genotype P = 0.0200, F<sub>1,36</sub> = 5.929. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT P = 0.0066; APP P = 0.278); (C) Both WT (n = 7) and APP (n = 8) mice sniffed a tube containing an heptanol solution over an empty tube (two-way ANOVA: interaction P = 0.8434, F<sub>1,26</sub> = 0.0398; object P = 0.0088, F<sub>1,26</sub> = 8.014; genotype P = 0.4825, F<sub>1,26</sub> = 0.5076. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT P = 0.0024; APP P = 0.0052); (D) Similarly, both WT and APP mice showed a preference for a tube containing a novel alcohol odor (heptanol:octanol solution) over the familiar one (heptanol alone) indicative that both genotypes can remember a familiar nonsocial odor. (Two-way ANOVA: interaction P = 0.3714, F<sub>1,26</sub> = 0.8272; object P = 0.0008, F<sub>1,26</sub> = 14.54; genotype P = 0.5262, F<sub>1,26</sub> = 0.4128. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT P = 0.0062; APP P = 0.001). Data are presented as mean ± SEM.
Figure 2. Activation of the β1-ADR is necessary for social recognition. On the left, representative diagram of the experimental design followed to assess social recognition (based on22). Blockage of the β1-ADR with various doses of betaxolol ranging from 0.01 to 1 mg/kg (n = 8 per group) did not affect social learning but impaired social recognition. (A) All mice injected with betaxolol or vehicle preferred a cup containing an unfamiliar C57Bl/6 mouse over an empty cup (two-way ANOVA: interaction P = 0.2924, F(3,54) = 1.274; object P < 0.0001, F(1,54) = 154.0; treatment P = 0.2459, F(3,54) = 1.424. Post hoc paired one-tailed t-test corrected for multiple comparisons: vehicle P = 0.0016; 0.01 mg/kg P = 0.0004; 0.1 mg/kg P = 0.0008; 1 mg/kg P = 0.0004). (B) However, mice injected with 0.1 or 1 mg/kg of betaxolol did not show a preference for a novel C56Bl/6 intruder mouse over a familiar one (not significant [ns] by paired t-test), indicative of impaired social recognition, while mice injected with vehicle or 0.01 mg/kg of betaxolol showed this preference (two-way ANOVA: interaction P = 0.0641, F(3,54) = 2.565; object P = 0.0004, F(1,54) = 14.29; treatment P = 0.0467, F(3,54) = 2.384. Post hoc paired one-tailed t-test corrected for multiple comparisons: vehicle P = 0.006; 0.01 mg/kg P = 0.0168; 0.1 mg/kg P = 0.5348; 1 mg/kg P = 0.3484); Betaxolol did not impair nonsocial odor recognition: (C) in a test of nonsocial odor recognition, betaxolol did not affect the preference of mice for a tube containing a heptanol solution over an empty tube (two-way ANOVA: interaction P = 0.4418, F(1,24) = 0.6117; object P < 0.0001, F(1,24) = 46.80; treatment P = 0.0254, F(1,24) = 5.680. Continued
Continued.
Post hoc paired one-tailed t-test corrected for multiple comparisons: vehicle $P = 0.0004$; betaxolol $P = 0.0016$ and (D) did not affect the ability of mice to discriminate between a familiar odor (heptanol) versus a new but similar odor (solution of heptanol-octanol) (two-way ANOVA: interaction $P = 0.3094$, $F_{(1,24)} = 1.079$; object $P < 0.0001$, $F_{(1,24)} = 33.22$; treatment $P = 0.1070$, $F_{(1,24)} = 2.804$. Post hoc paired one-tailed t-test corrected for multiple comparisons: vehicle $P = 0.0018$; betaxolol $P = 0.0014$). (E) Systemic injection of xamoterol (3 mg/kg) prior to social recognition testing did not affect the preference of WT ($n = 10$) and APP ($n = 10$) mice for an unfamiliar intruder over an empty cup (two-way ANOVA: interaction $P = 0.0011$, $F_{(1,36)} = 12.67$; object $P < 0.0001$, $F_{(1,36)} = 118.3$; treatment $P < 0.0001$, $F_{(1,36)} = 22.19$. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT $P < 0.001$; APP $P < 0.001$); But (F) rescued the social recognition deficit observed previously in APP mice (see Fig. 1B); similar to their WT control littersmates injected with xamoterol ($n = 10$), xamoterol injected APP mice ($n = 10$) showed preference for a novel intruder over a familiar one (two-way ANOVA: interaction $P = 0.0231$, $F_{(1,36)} = 5.636$; object $P < 0.0001$, $F_{(1,36)} = 35.09$; treatment $P < 0.0001$, $F_{(1,36)} = 20.71$. Post hoc paired one-tailed t-test corrected for multiple comparisons: WT $P = 0.0198$; APP $P < 0.001$).

nonsocial odors (Fig. 1C and D). APP mice display a general hyperactivity and spend more time sniffing social objects during the learning phase and the social recognition phase of the test compared to the WT mice ($P < 0.001$ and $P = 0.046$, respectively). This hyperactivity phenotype was previously reported in other behavioral assays, such as the open field test.\textsuperscript{20} We show for the first time that this APP mouse model of AD recreates one important symptom characteristic of AD, the selective inability to recognize a previously met individual while displaying intact odor and object discrimination.

\textbf{\textit{\textbeta_{1}}-ADR and its downstream signaling is essential for learning of social cues}

Because expression of the\textbeta_{1}-ADR has been suggested to play a critical role in AD pathology,\textsuperscript{16} we then investigated the potential contribution of the\textbeta_{1}-ADR in social recognition to determine whether the abnormalities in the\textbeta_{1}-noradrenergic neurotransmission in APP mice could be responsible for their social memory defect. We assessed the ability of C57Bl/6 mice to recognize a previously met conspecific after an acute subcutaneous injection of various doses of a selective\textbeta_{1}-ADR antagonist, betaxolol (0.01, 0.1, and 1 mg/kg). Although betaxolol did not affect the preference for an unfamiliar intruder over an empty cup, 0.1 and 1 mg/kg of betaxolol resulted in an inability of mice to distinguish between a new and a familiar conspecific without affecting the total time spent exploring the two conspecifics (Fig. 2A and B). This finding was reproduced in a different behavioral paradigm that also assesses social recognition, the three-chamber test (Fig. S1A). We then demonstrated that blockade of\textbeta_{1}-ADR affects the recognition of social cues without affecting general olfactory abilities and discrimination (Fig. 2C and D). These results were confirmed in an odor habituation/dishabitation paradigm (Fig. S1B). Finally, we observed that the ability to remember a familiar object was not different in the mice injected with betaxolol or vehicle when conducted with an identical experimental design and apparatus (Fig. S1C).

These results suggest that the\textbeta_{1}-ADR activation is necessary for social learning and recognition in mice. We thus propose that abnormalities in the\textbeta_{1}-ADR signaling in the APP mice are responsible for their deficit in social recognition, and therefore restoring the function of the\textbeta_{1}-ADR in APP mice would rescue the social recognition deficit. Indeed, injection of the\textbeta_{1}-ADR partial agonist, xamoterol in APP mice prior to social learning rescued the deficit otherwise observed (Fig. 2E and F).

Our pharmacological data indicate that the\textbeta_{1}-ADR is necessary for social recognition. As drug selectivity for a specific receptor is often relative, we aimed to test social recognition abilities in both\textbeta_{1}-ADR KO and\textbeta_{2}-ADR KO mice and their FVB controls to confirm: (1) that betaxolol targets specifically the\textbeta_{1}-ADR, and (2) the importance of the\textbeta_{1}-ADR (vs.\textbeta_{2}-ADR) in social recognition. All mice showed a preference for a cup with an unfamiliar intruder over an empty cup. Whilst\textbeta_{1}-ADR KO mice have impaired social recognition (Fig. 3A),\textbeta_{2}-ADR KO mice perform the task correctly (Fig. 3B). In addition, betaxolol injection in\textbeta_{2}-ADR KO mice prior to social learning resulted in impaired social recognition (Fig. 3B). This suggests that the social recognition deficit induced by betaxolol is mediated by the\textbeta_{1}-ADR not\textbeta_{2}-ADR and that the\textbeta_{1}-ADR is essential for social recognition.

We next evaluated if the activation of the\textbeta_{1}-ADR is important for the acquisition of social cues (social learning) or during the retrieval of this information. We injected betaxolol either 20 min before the learning phase of the test or 30 min before the retrieval phase of the test. Inhibition of\textbeta_{1}-ADR during the learning phase led to a social recognition deficit (Fig. 3D), while inhibition of\textbeta_{1}-ADR during the retrieval phase of the test did not impair social recognition (Fig. 3C). We then confirmed the importance of the\textbeta_{1}-ADR for long-term consolidation of social cues by injecting Betaxolol before the learning phase and 24 h prior to the social recognition test. Mice injected with betaxolol prior to the learning phase and tested 24-h later showed impaired social recognition, while vehicle-injected mice had intact social recognition.
The β1-ADR in the MeA is essential for social recognition

Brain regions involved in social recognition have already been defined.26,27 Among them are the lateral septum, prefrontal cortex, and MeA. We first confirmed the importance of the MeA for social recognition. We used c-Fos as a marker of neuronal activity and compared its expression in a group of C57Bl/6 mice after social learning with a group of mice after both social learning and social recognition. Unbiased stereological counting revealed higher level of c-Fos expression after social recognition in the MeA (Fig. S2A) but not in the basolateral amygdala (Fig. S2B) confirming the importance of the MeA for the processing of social cues.

We then observed that after injection of betaxolol, c-Fos expression in MeA was significantly reduced after social recognition compared to vehicle-injected group (Fig. 4A). This reduction was specific to regions activated during social recognition such as the MeA as we did not observe such an effect in the paraventricular nucleus of the thalamus, which is poor in β1-ADR and not preferentially activated by social recognition (Fig. S2C).

To further confirm the role of the β1-ADR in the MeA for social recognition, betaxolol was directly injected in the MeA (Fig. 4B) of C57Bl/6 mice prior to social learning. Mice treated with betaxolol in the MeA were not able to recognize a familiar conspecific (Fig. 4C). Our results demonstrated that the MeA is an important structure for social recognition, and that activation of β1-ADR in the MeA is necessary for social learning and recognition.

The β1-ADR is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein. As such, one of the signaling pathways downstream of the β1-ADR involves activation of the cAMP/PKA cascade resulting in phosphorylation of CREB. We thus analyzed whether the blockade of the pathway downstream of β1-ADR by PKI 14-22 a selective PKA inhibitor impairs social learning and recognition. PKI 14-22 was in the MeA of C57Bl/6 mice prior to social learning to determine whether blockade of the PKA/CREB/pCREB cascade affects social recog-
Inhibition of PKA impairs the ability of mice to recognize a familiar conspecific (Fig. 4D) without affecting the preference for an unfamiliar intruder over an empty cup during social learning. These results show that PKA activity is necessary for social learning and recognition. Together our results show that inhibition of β1-ADR signaling pathway in MeA by betaxolol or a PKA inhibitor results in social recognition deficits.

**β1-ADR modulates CREB phosphorylation**

Because one of the well-known downstream target of PKA is CREB phosphorylation, we aimed at evaluating the possible role of pCREB in social learning; we performed a series of experiments: we first observed that in C57Bl/6 mice learning of social cues induced a strong increase in pCREB in the MeA which picked 5 min after the onset of social learning and returned to baseline after 10 min (Fig. 5A). We then tested whether pharmacological modulation of β1-ADR affects CREB phosphorylation in the MeA in the context of social learning. We showed that blockade of the β1-ADR by an acute systemic injection of 1 mg/kg of betaxolol before social learning inhibits the induction of pCREB after social learning (Fig. 5B) while activation of the β1-ADR with 3 mg/kg of the partial agonist xamoterol increases pCREB (Fig. 5C). With the present data, we show that activation of the PKA/pCREB cascade downstream of the β1-ADR mediates social learning and recognition.
To assess whether the rescuing effects of xamoterol on social memory in APP mice is associated with modifications in the level of pCREB, we first measured the level of pCREB in the MeA of APP mice and their WT littermates and found a higher level of pCREB in MeA of APP mice (Fig. S3). It was reported that in AD several phosphorylated proteins and transcription factors are preferentially located in the cytoplasm (vs. the nucleus) and are thus inefficient in inducing expression of genes important for learning and memory. We thus determined whether the level of pCREB in the nucleus of APP mice (effective pCREB) was affected by xamoterol. We observed that despite the high levels of pCREB in whole tissue lysates of MeA in APP mice, the levels of pCREB in nuclear fraction of the tissue was lower in APP mice compared to control mice and xamoterol increased pCREB level in the nuclear fraction of the MeA in APP mice (Fig. 5D). This indicates that activation of the β₁-ADR in a mouse model...
of AD using the partial agonist xamoterol leads to an increased level of nuclear pCREB in the MeA and an improvement in learning of the social cues.

Discussion

Many neurological disorders, such as AD, are characterized by impairment in social memory and discrimination. The causes of these symptoms are not yet well-defined and as a consequence, no treatment currently exists to rescue these deficits. We have now identified the β₁-ADR and it downstream PKA/pCREB signaling cascade as key modulators of social learning and recognition. Interestingly, we have shown pathological changes in this cascade in a model of AD. We have shown that the level of nuclear pCREB in the MeA of APP mice is significantly reduced when compared to WT mice. Moreover, we have shown that APP mice present severe social learning and recognition deficits, that relies mainly on integrity of the MeA. Finally, we have shown that a selective partial agonist of the β₁-ADR can restore this function by increasing the level of nuclear pCREB in the MeA, highlighting a possible approach for improving or restoring social function in AD.

We have reported that APP mice display social recognition deficits, despite demonstrating normal recognition for nonsocial olfactory cues. Even if at the level of the olfactory bulb, NA has been shown to be important for the processing of neutral and social olfactory information by promoting selective attention to olfactory stimuli, our results indicate that two independent pathways downstream of the olfactory bulb regulate memory for social and nonsocial cues. For the first time, we show that the blockade of the β₁-ADR prior to learning social or neutral olfactory cues leads to impaired social recognition without affecting nonsocial olfactory recognition. In addition, our results indicate that the β₁-ADR pathway is necessary for the learning of social cues but not for their recall.

The MeA is known to be involved in the processing of sensory information necessary for the regulation of social and sexual behaviors in both humans and nonhuman mammals. Many previous rodent studies have shown the central role of the MeA for social recognition. Several studies have demonstrated pathological changes occur in amygdala at the early stages of AD and accumulation of neuritic plaques and neurofibrillary tangles is observed in amygdala. The early impairment of amygdala structures, whose central role in the recognition and memorization of emotions has been demonstrated, has been associated with deficits in terms of social cognition in AD. Furthermore, positron emission tomography studies in AD patients during face memory task have pointed toward dysfunction of the amygdala. Our results demonstrate the importance of β₁-ADR noradrenergic neurotransmission in the MeA for social recognition, and suggest that abnormality in this signaling cascade in this brain region in APP mice could contribute to the disease related social recognition deficit.

Our data indicate that the β₁-ADR in MeA regulates social learning by activation of the PKA/CREB phosphorylation-signaling cascade. Indeed, pharmacological inhibition of PKA in the MeA prior to social learning impairs social recognition. We also demonstrate that blockade of β₁-ADR with a selective antagonist which induces social recognition deficit results in a severe decrease in CREB phosphorylation in the MeA. These results specify a direct link between the PKA/pCREB cascade and social learning in mice. Generally it is assumed that pCREB is necessary for long-term memory, rather than short-term memory, because of its known effect on gene expression and protein synthesis that are required for long-term memory. However, Suzuki et al. recently demonstrated that an upregulation of CREB activity leading to higher expression of brain-derived neurotrophic factor enhances social and nonsocial short-term memory in mice. Here, we are suggesting that a similar phenomenon is occurring as a consequence of activation of the β₁-ADR. Social learning induces the release of NA, which activates β₁-ADR in the MeA, leading to activation of the cAMP/PKA/pCREB signaling cascade. We have shown that activation of β₁-ADR and its downstream signaling is necessary for the learning of social cues.

While a treatment with the β₁-ADR partial agonist xamoterol rescues the social recognition deficit observed in APP mice, it did not affect their total level of pCREB but did show significantly increased levels of nuclear pCREB. Therefore, we suggest that social recognition deficit observed in APP mice is explained rather by diminished levels of nuclear pCREB. It has been shown in cellular system that high levels of amyloid-beta causes hyperphosphorylation of CREB and a lack of nuclear translocation. Therefore, we suggest that activation of the β₁-ADR with xamoterol affects the nuclear level of pCREB in the MeA of APP mice and activates mechanisms allowing the processing of social cues necessary for further social recognition.

Finally, our findings indicate that the β₁-ADR can be used as a potential therapeutic target to improve the social memory and possibly other cognitive deficits in AD. Our conclusions are based on the APP mouse model of AD which has been shown to be highly successful for AD treatment compound testing. However, due to significant involvement of the noradrenergic system in cardiovascular function, further safety and translational studies will be needed to ensure the safety and efficacy.
of this approach. Ultimately developing a molecule with minimal systemic activity and high central nervous system (CNS) penetration may provide us with means to enhance the positive CNS effects of adrenergic system while minimizing the cardiovascular effects. While this novel cognitive enhancement strategy remains extremely attractive, further investigation of the β1-ADR as modulator of the neuroinflammation is also warranted.

Acknowledgments

We thank Leo Kim and Nay Saw for excellent technical assistance. We also thank R. G. Giffard and D. Bernstein for providing us with β2-ADR KO and β1-ADR KO mice, respectively. This study was partially supported by National Institute of Neurological Disorders and Stroke P30 center core grant (NS069375-01A1).

Conflict of Interest

None declared.

References

1. Werheid K, Clare L. Are faces special in Alzheimer’s disease? Cognitive conceptualisation, neural correlates, and diagnostic relevance of impaired memory for faces and names. Cortex 2007;43:898–906.
2. Wilson RS, Kasziak AW, Bacon LD, et al. Facial recognition memory in dementia. Cortex 1982;18:329–336.
3. Bielsky IF, Hu SB, Szegda KL, et al. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004;29:483–493.
4. Young LJ. The neuroscience of social recognition, approach, and avoidance. Biol Psychiatry 2002;51:18–26.
5. Higashida H, Yokoyama S, Huang JJ, et al. Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38. Neurochem Int 2012;61:828–838.
6. Meynen G, Unmehopa UA, Hofman MA, et al. Hypothalamic vasopressin and oxytocin mRNA expression in relation to depressive state in Alzheimer’s disease: a difference with major depressive disorder. J Neuroendocrinol 2009;21:722–729.
7. Mazurek MF, Beal MF, Bird ED, Martin JB. Oxytocin in Alzheimer’s disease: postmortem brain levels. Neurology 1987;37:1001–1003.
8. Bondareff W, Mountjoy CQ, Roth M, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1987;1:256–262.
9. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 1981;49:419–428.
10. Gibbs ME, Summers RJ. Role of adrenergic subtypes in memory consolidation. Prog Neurobiol 2002;67:345–391.
11. Madison DV, Nicoll RA. Norepinephrine decreases synaptic inhibition in the rat hippocampus. Brain Res 1988;442:131–138.
12. Murchison CF, Zhang XY, Zhang WP, et al. A distinct role for norepinephrine in memory retrieval. Cell 2004;117:131–143.
13. Kleschevnikov AM, Belichenko PV, Salehi A, Wu C. Discoveries in Down syndrome: moving basic science to clinical care. Prog Brain Res 2012;197:199–221.
14. Faizi M, Bader PL, Tun C, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 2011;43:397–413.
15. Salehi A, Faizi M, Colas D, et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 2009;1:7ra17.
16. Bullido MJ, Ramos MC, Ruiz-Gomez A, et al. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer’s. Neurobiol Aging 2004;25:853–859.
17. Marino MD, Bourdelat-Parks BN, Cameron Liles L, Weinschenker D. Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav Brain Res 2005;161:197–203.
18. Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006;26:1343–1354.
19. Rockensten E, Mallory M, Mante M, et al. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta (1–42). J Neurosci Res 2001;66:573–582.
20. Faizi M, Bader PL, Saw N, et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer’s disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav 2012;2:142–154.
21. Nadler JI, Moy SS, Dold G, et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav 2004;3:303–314.
22. Macbeth AH, Edds JS, Young WS III. Housing conditions and stimulus females: a robust social discrimination task for studying male rodent social recognition. Nat Procot 2009;4:1574–1581.
23. Paxinos G, Franklin KB. The mouse brain in stereotaxic coordinates. Compact 2nd ed. Amsterdam, Boston: Elsevier Academic Press, 2004.
24. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in
Supporting Information

Additional Supporting Information may be found in the online version of this article:

Data S1. Supplementary methods.

Figure S1. Blocking the \( \beta_1 \)-ADR with betaxolol (1 mg/kg) impaired social recognition independently of nonsocial odor recognition and object recognition. (A) In the three-chamber social recognition test, systemic injection of betaxolol prior the learning phase of the test did not alter the preference of mice for an unfamiliar intruder in a cup over an empty cup (vehicle-injected mice \( n = 10 \), betaxolol-injected mice \( n = 10 \)) (two-way ANOVA interaction: \( P = 0.2801 \), \( F_{(1,36)} = 1.203 \); object \( P < 0.001 \), \( F_{(1,36)} = 33.05 \); treatment \( P = 0.6501 \), \( F_{(1,36)} = 0.2093 \). Post hoc paired one-tailed \( t \)-test corrected for multiple comparisons: vehicle \( P = 0.0004 \); betaxolol \( P = 0.0014 \). However, betaxolol impairs social recognition: betaxolol-injected mice did not show a preference for a new intruder over a familiar one while vehicle-injected mice show this preference (two-way ANOVA interaction: \( P = 0.0906 \), \( F_{(1,36)} = 3.024 \); object \( P = 0.0293 \), \( F_{(1,36)} = 5.155 \); treatment \( P = 0.6749 \), \( F_{(1,36)} = 0.1789 \). Post hoc paired one-tailed \( t \)-test correlated for multiple comparisons: vehicle \( P = 0.0082 \); betaxolol \( P = 0.7128 \). (B) Betaxolol did not impair nonsocial odor recognition; in a test of nonsocial odor habituation, dishabituation, and recognition, both vehicle-injected (\( n = 10 \)) and betaxolol-injected (\( n = 10 \)) mice habituated to nonsocial odors (water and vanilla) over the course of three successive exposures and dishabituated when presented to a new odor (two-way RM ANOVA: interaction: \( P = 0.9623 \), \( F_{(6,108)} = 0.2401 \); treatment \( P = 0.5234 \), \( F_{(1,108)} = 0.4236 \); object \( P < 0.0001 \), \( F_{(6,108)} = 21.42 \); Post hoc paired one-tailed \( t \)-test correlated for multiple comparisons: Water habituation: vehicle \( *** P < 0.001 \); betaxolol \( ** P < 0.001 \); Water dishabituation: vehicle \( ** P = 0.0024 \); betaxolol \( *** P < 0.001 \); Vanilla habituation: vehicle \( *** P < 0.001 \); betaxolol \( ** P = 0.006 \). All mice were also able to discriminate between a previ-

© 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
ously presented odor (vanilla) and a new odor (mint) as indicated by higher sniffing time when presented with the mint odor versus sniffing time when presented with the vanilla odor for a third time (vehicle **P = 0.0048; betaxolol °P = 0.0036) (C) The ability of mice to recognize a familiar object over a new one was not affected by betaxolol. Both vehicle-injected (n = 10) and betaxolol-injected (n = 10) mice preferred a new object over a familiar one in an object recognition test (two-way ANOVA interaction: P = 0.7487, F(1,36) = 0.1042; object P < 0.0001 F(1,36) = 28.12; treatment P = 0.2604, F(1,36) = 0.2604; Post hoc paired one-tailed t-test correlated for multiple comparisons: vehicle P < 0.001; betaxolol P < 0.001). Data are presented as mean ± SEM.

Figure S2. (A) c-Fos expression is induced in the MeA 90 min after social recognition. Quantification of c-Fos positive cells was performed using a nonbiased stereological methods in control mice (n = 4) and mice exposed to a social recognition task (n = 4) (P = 0.0303 by t-test). (B) c-Fos expression was not induced in the basolateral amygdala (BLA) after social recognition. Quantification of c-Fos positive cells was performed using a nonbiased stereological methods in control mice (n = 4) and mice exposed to a social recognition task (n = 4) (P = 0.4857 by Mann–Whitney test). (C) Injection of betaxolol prior to testing in a social recognition task did not affect the number of c-Fos positive cells in the thalamus (PV), brain region not involved in social memory and poor in β1-ADR (vehicle-injected mice n = 4; betaxolol-injected mice n = 4; P = 0.8571 by Mann–Whitney test). Data are presented as mean ± SEM. Scale bars, 100 µm (magnified box) and 200 µm.

Figure S3. Western blot analysis of pCREB performed on whole tissue homogenates from medial amygdala of control mice and APP mice (n = 4 per group). pCREB level was significantly higher in APP mice (P = 0.0286 by Mann–Whitney test). The relative optical density is normalized to CREB. Data are presented as mean ± SEM.